Lilly renews speedway diabetes awareness campaign

Share this article:
Eli Lilly & Co. is taking its Vision Racing Wellness Tour on another lap around the racing circuit, offering fans free diabetes screening.

The campaign, in its second year, partners Indianapolis-based Lilly with Vision Racing, a racing team that competes in the Indy Racing League, whose races include the Indianapolis 500. Drivers Ed Carpenter and Ryan Hunter-Reay will serve as “ambassadors” for the tour, which will offer diabetes screenings with A1c testing and risk factor assessment in addition to blood pressure and cholesterol screening through May at the Indianapolis Motor Speedway before moving on to races in West Allis, WI; Fort Worth, Texas; Newton, IA; Richmond, VA and Lexington, Ohio.

Lilly VP and chief marketing officer Rob Brown called it: “a great opportunity to bring a truly unique health offering to the track. In select cities, IndyCar race fans will have access to a certified diabetes educator in addition to the diabetes screenings at the Wellness Tour. Through these offerings, Lilly hopes to help people stay on track with their health.”

Lilly diabetes products include Byetta, Humulin, Humalog and Glucagon.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...